Skip to main content
Enter your The Contraceptive Pipeline Database username.
Enter the password that accompanies your username.
Liletta LNG IUS
Levosert (U.K.), Erlacela (Portugal), Donasert (Romania)
SRA/WHO PQ Approved
LILETTA is the brand name for the levonorgestrel-releasing intrauterine system (LNG-IUS) marketed by Medicines360 and Actavis in the U.S., where it is approved for 3 years of use for contraception.
May 30, 2018
Active Pharmaceutical Ingredient (API):
Drug reservoir: Silicone base; T-frame: low density polyethylene (LDPE), etc. See footnote
Potential Multi-Purpose Technology (MPT):
Medicines360 received U.S. FDA approval for Liletta in February 2015 and the product launched in the U.S. in April 2015.
As of April 2015, the product is also approved in more than a dozen countries in Europe, including in the U.K. for 3 years of contraception and treatment of menorrhagia.
In 2014, a public-private partnership was launched between Medicines360, FHI 360 and Marie Stopes International (MSI) to support the development of an introduction strategy for the product in Kenya.
Medicines360's aims to ensure affordable access to high-quality health products for women in the U.S. and the developing world. Medicines360 is pursuing partnerships and registrations in developing countries, where the LNG-IUS could provide substantial benefits to women.
Liletta website #1
Liletta website #2
For additional inactive materials, see product website: www.liletta.com
Download Product Report